NASDAQ: LAB · Life Sciences · 6 alerts · CIK 1162194
Share price
$0.6210Close, Nov 16
Market cap
$245M
Shares outstanding
394.79MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Standard Biotools Inc. filings on SEC EDGAR ↗
Standard BioTools Inc. completed the sale of its Microfluidics business to healthcare investment firm ARCHIMED. The divested business will now operate as a standalone independent entity named Biomark Scientific, focusing on high-throughput genomic profiling and microfluidics technology.
Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days and represents a strategic action to streamline the company's portfolio. Financial terms of the divestiture were not disclosed in the filing.
Standard Biotools Divestiture to Element Biosystems, LLC for $5.5M
Standard BioTools terminated its previous agreement with Multiplex Bio and entered into a new definitive agreement to sell its mass cytometry business to Element Biosystems for $5.5 million in cash. The board determined the unsolicited offer from GMT Venture was a superior proposal, as it provides higher cash proceeds and eliminates a previously required $10 million working capital loan. The divestiture is expected to close by the end of 2026, concurrently with the company's pending merger with Treeline Biosciences.
Value
$5.5M
Counterparty
Element Biosystems, LLC (subsidiary of GMT Venture Partners, LLC)